China’s strong determination in chronic disease prevention and control, as well as its clear policy goals and actions, are highly admirable, said Helge Lund, chairman of global pharmaceutical giant Novo Nordisk, in an interview with CMG. He added that his company will continue to contribute to the Chinese healthcare market.